Finance

Beta
Lists
GSK:BCBA
Glaxosmithkline CEDEAR
ARS 18,390.00
-0.05%
(-10.00) 1D
Jun 2, 5:00:00 PM GMT-3  ·   ARS
All symbols
SymbolPriceChange% Change
Generating top insights for GSK...
Open
ARS 18,320.00
High
ARS 18,480.00
Low
ARS 18,180.00
Mkt. cap
74.28B
Avg. vol.
521.00
Volume
0.00
52-wk high
ARS 22,760.00
52-wk low
ARS 11,150.00
Shares outstanding
4.05B
No. of employees
67K
Open
ARS 18,320.00
High
ARS 18,480.00
Low
ARS 18,180.00
Mkt. cap
74.28B
Avg. vol.
521.00
Volume
0.00
52-wk high
ARS 22,760.00
52-wk low
ARS 11,150.00
Shares outstanding
4.05B
No. of employees
67K
News stories
From sources across the web
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England. GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500. The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK. The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About Glaxosmithkline CEDEAR
CEOEmma Walmsley | Emma Walmsley
Employees66.8K
FoundedDec 27, 2000
Headquarters-
SectorPharmaceutical industry
Websitegsk.com
Previous reportsAll values in GBP
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in GBP
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
7.99B
8.55B
8.62B
7.63B
Cost of goods sold
2.16B
2.24B
2.62B
1.87B
Cost of revenue
2.16B
2.24B
2.62B
1.87B
Research and development expenses
1.54B
1.58B
2.14B
1.52B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.13B
2.16B
2.67B
2.08B
Operating expense
3.43B
3.23B
4.37B
2.99B
Total operating expenses
5.59B
5.46B
6.99B
4.86B
Operating income
2.39B
3.08B
1.63B
2.77B
Other non operating income
-
-
-21.00M
-
EBT including unusual items
1.89B
2.46B
950.00M
2.14B
EBT excluding unusual items
2.26B
2.94B
1.48B
2.62B
Income tax expense
241.00M
312.00M
223.00M
305.00M
Effective tax rate
12.77%
12.70%
23.47%
14.23%
Other operating expenses
-246.00M
-511.00M
-434.00M
-615.00M
Net income
1.44B
2.01B
636.00M
1.74B
Net profit margin
18.07%
23.55%
7.38%
22.77%
Earnings per share
0.46
0.55
-
-
Interest and investment income
50.00M
26.00M
17.00M
22.00M
Interest expense
-184.00M
-167.00M
-145.00M
-167.00M
Net interest expenses
-134.00M
-141.00M
-128.00M
-145.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
3.55B
3.82B
2.69B
3.23B
Gain or loss from assets sale
-
-
-40.00M
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer